Story · Medicine & Biotech
Jon Wigginton: FDA Complete Response Letter for Ivonescimab in Post-TKI NSCLC
1 outlet · first reported by OncoDaily on
Jon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn: “Ivonescimab BLA seeking approval in patients with locally-advanced or metastatic NSCLC post TKI rejected by FDA (OncoDaily)
Coverage, in order
-
Jon Wigginton: FDA Complete Response Letter for Ivonescimab in Post-TKI NSCLCJon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn: “Ivonescimab BLA seeking approval in patients with locally-advanced or metastatic NSCLC post TKI rejected by FDA
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.